AB Science to Launch Asthma Drug Study with FDA Approval

AB Science is to commence its Phase III study of masitinib in severe persistent asthma.

French pharmaceutical company AB Science has received investigational new drug status from the US FDA, allowing it to commence its Phase III study of masitinib in severe persistent asthma.

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells, which play a role in various cancers.

The double-blind, international, multicentre, randomised, placebo-controlled, two-parallel groups study will compare the efficacy and the safety of masitinib at 6mg/kg/day against placebo in the treatment of patients with severe persistent asthma uncontrolled with oral corticosteroids.